Success Metrics

Clinical Success Rate
84.6%

Based on 22 completed trials

Completion Rate
85%(22/26)
Active Trials
2(6%)
Results Posted
55%(12 trials)
Terminated
4(12%)

Phase Distribution

Ph not_applicable
7
21%
Ph phase_2
9
27%
Ph phase_4
14
42%
Ph phase_3
1
3%

Phase Distribution

0

Early Stage

9

Mid Stage

15

Late Stage

Phase Distribution31 total trials
Phase 2Efficacy & side effects
9(29.0%)
Phase 3Large-scale testing
1(3.2%)
Phase 4Post-market surveillance
14(45.2%)
N/ANon-phased studies
7(22.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

81.5%

22 of 27 finished

Non-Completion Rate

18.5%

5 ended early

Currently Active

2

trials recruiting

Total Trials

33

all time

Status Distribution
Active(2)
Completed(22)
Terminated(5)
Other(4)

Detailed Status

Completed22
unknown4
Terminated4
Active, not recruiting1
Recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
33
Active
2
Success Rate
84.6%
Most Advanced
Phase 4

Trials by Phase

Phase 29 (29.0%)
Phase 31 (3.2%)
Phase 414 (45.2%)
N/A7 (22.6%)

Trials by Status

active_not_recruiting13%
completed2267%
recruiting13%
withdrawn13%
unknown412%
terminated412%

Recent Activity

Clinical Trials (33)

Showing 20 of 33 trialsScroll for more
NCT01351753Phase 2

Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity

Terminated
NCT05579249Phase 4

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

Completed
NCT06854614Phase 4

Sequential or CombinaTion Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)

Active Not Recruiting
NCT05816343Phase 2

Long Term Efficacy and Safety of Orlistat for Type 1 Hyperlipoproteinemia

Recruiting
NCT04531176Phase 4

EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial

Terminated
NCT06501326Phase 4

Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease

Unknown
NCT03582722Phase 4

Weight Loss Aid in an Exposed Population

Completed
NCT05496075Phase 4

Orlistat Reduces Uric Acid in Overweight/Obese Patients With Hyperuricemia

Completed
NCT02767531Phase 2

Orlistat for the Treatment of Type I Hyperlipoproteinemia

Completed
NCT02432209Phase 3

Improving Reproductive Fitness Through Pretreatment With Lifestyle Modification in Obese Women With Unexplained Infertility

Completed
NCT01675154Phase 2

Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia

Terminated
NCT01003483Phase 2

Metformin Versus Orlistat in Obese Polycystic Ovary Syndrome (PCOS) Patients

Completed
NCT02069197Phase 2

Ketogenic Diet Treatment of Obesity With Co-morbid Type 2 Diabetes Mellitus and/or Obstructive Sleep Apnea

Unknown
NCT01597531Phase 4

Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding

Terminated
NCT03383068Phase 4

Research of Intensive Metabolic Intervention Before Pregnancy in PCOS

Unknown
NCT00422058Phase 2

The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes

Completed
NCT02706067Phase 4

Multifactorial Approach Associated With Orlistat (Xenical) for 4 Years Weight Loss Maintenance in Obese Adults

Completed
NCT01719419Not Applicable

The Effect of Modified Sham Feeding With Orlistat in Overweight and Obese Subjects

Withdrawn
NCT00108524Not Applicable

A Low-Carbohydrate, Ketogenic Diet Versus Orlistat for Weight Loss

Completed
NCT01035333Phase 4

A Pilot Study of the Efficacy of Alli in the Management of Pre-operative Weight Loss Required for Bariatric Surgery.

Completed

Drug Details

Intervention Type
DRUG
Total Trials
33